查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1863278

勃起功能障礙治療設備市場按產品類型、適應症、年齡層、材質、作用機制、電源、最終用戶和分銷管道分類－2025年至2032年全球預測

Erectile Dysfunction Devices Market by Product Type, Indication, Age Group, Material Type, Mechanism of Action, Power Source, End-User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，治療勃起功能障礙的設備市場將成長至 28 億美元，複合年成長率為 6.35%。

關鍵市場統計數據
基準年 2024 17.1億美元
預計年份：2025年 18.1億美元
預測年份 2032 28億美元
複合年成長率 (%) 6.35%

全面概述了當前治療勃起功能障礙的器械領域，重點介紹了技術進步、相關人員的需求以及不斷發展的患者照護路徑。

引言部分將當前勃起功能障礙治療器材的現狀置於快速的臨床創新、不斷變化的醫保報銷模式以及患者對微創解決方案日益成長的期望等背景下進行闡述。近年來，技術進步拓展了治療選擇，使其不再局限於第一線藥物治療，而是為植入式解決方案、輔助性功能增強裝置和非侵入性治療方法創造了空間。同時，以病人為中心的治療路徑也日益受到重視，便利性、隱密性和生活品質的提升成為推動治療方案普及的關鍵因素。

臨床、生產和分銷管道的相關人員正面臨著一個動態變化的環境，監管政策的清晰度和支付方的政策日益影響著產品設計和上市策略。臨床醫生會仔細檢視產品的耐用性、併發症發生率和功能性結果，而採購團隊則需要在設備效能、庫存和訓練成本之間取得平衡。同時，患者擴大參與治療方案的選擇中，優先考慮那些符合自身生活方式且安全性已得到驗證的設備。在此背景下，市場在多個維度上呈現日益明顯的差異化，包括設備的作用機制、材質成分、動力來源和終端用戶環境，這些因素正在塑造產品的市場接受度和競爭定位。

這份介紹簡報闡明了製造商和投資者需要將臨床證據、設計創新和商業性執行結合的必要性。透過將產品屬性與實際治療路徑和分銷情況聯繫起來，企業可以更好地優先分配研發資源，並打入市場策略。

臨床創新、監管調整和分銷管道轉型將如何整合，從而重新定義勃起功能障礙醫療器材生態系統的價值創造？

該領域的變革性變化是由臨床、技術和市場力量的融合所驅動的，重新定義了價值創造。在臨床上，微創和可逆治療方法的興起凸顯了低強度超音波和衝擊波療法等治療設備的重要性，這些設備提供了非手術治療途徑，使更多患者受益。同時，植入設計的創新（包括充氣式和半剛性植入的改進）優先考慮可靠性、易於植入性和患者舒適度。這些技術進步日益受到材料科學發展的影響，包括彈性聚合物、矽酮、不銹鋼和鈦等金屬合金以及兼俱生物相容性和機械功能的聚氨酯配方。

從監管和報銷的角度來看，更清晰的證據標準和基於價值的採購討論正鼓勵製造商在研發早期階段就提供療效和耐久性方面的比較數據。這種轉變有利於那些能夠證明其產品在主要適應症、次要適應症和多適應症（包括老齡化相關、神經系統、血管、內分泌和心理因素等病因）方面均取得顯著療效的公司。同時，分銷管道的演變正在改變市場准入模式。線上平台降低了消費者參與的門檻，而傳統的專科零售商和醫院採購系統在複雜器械和手術方面仍然發揮著重要作用。這些趨勢正在促使醫療設備製造商、臨床相關人員和分銷合作夥伴之間建立策略聯盟，以在控制成本和複雜性的同時加速產品推廣應用。

從本質上講，市場格局正在從以產品為中心的提案轉向綜合護理解決方案，其中證據、可用性和分銷策略共同決定了商業性成功。

評估2025年美國關稅對醫療設備供應鏈和定價策略的累積營運、商業和採購影響

2025年實施的定向關稅迫使相關人員重新評估其供應鏈結構、籌資策略和成本轉嫁動態。依賴跨境零件的製造商，尤其是那些生產精密植入和電療設備的製造商，正面臨不斷上漲的投入成本和日益複雜的物流挑戰。為此，一些製造企業正在評估回流、近岸外包或多源採購等策略，以降低關稅風險，同時確保品管和合規性。擁有一體化製造地和完善品質系統的策略供應商則更有能力應對和管理關稅波動，而不會影響產品的連續性。

除了製造業之外，關稅也影響分銷通路的經濟效益和定價策略。零售商和專業分銷商必須權衡利潤壓力與市場競爭地位，在某些情況下，他們需要重新談判供應商合約並整合庫存單位（SKU），以維持存貨周轉和價格穩定。醫院和專科診所正在修訂採購標準，更加重視整體擁有成本和長期服務協議，而非僅依賴單價，減輕臨時關稅上調帶來的預算影響。此外，不斷變化的政策環境正在加速有關雙邊供應商協議和戰略庫存緩衝的討論，以確保擇期手術的連續性。

尤其值得注意的是，關稅環境凸顯了供應商可追溯性和零件採購路徑在監管文件中透明化的重要性。積極記錄其供應鏈韌性、實施雙重採購策略並向支付機構和採購利益相關人員傳達成本管理計劃的公司，將更有利於應對不確定性並維持市場進入。

細分市場分析洞察：揭示分銷管道對產品差異化、適應症複雜性、人口統計因素、材料選擇、作用機制選擇和策略定位的影響

細分市場分析揭示了產品差異化的多面性，以及研發和商業化與臨床及終端用戶需求保持一致的重要性。依產品類型分類，市場可分為陰莖植入、輔助器具、治療裝置和真空壓迫裝置。陰莖植入本身又可分為植入，兩者在機械複雜性、病患滿意度和手術訓練要求方面各有優劣。輔助器具分為夾式和環式壓迫裝置，與植入相比，通常定位為輔助治療或微創治療方案。治療裝置包括低強度脈衝超音波設備和衝擊波治療裝置，這些裝置無需植入，專注於再生醫學，旨在治療潛在的血管和組織疾病。

基於適應症的細分提供了更細緻的視角。必須從混合型、原發性和續發性勃起功能障礙的角度來理解市場。混合型勃起功能障礙通常涉及老齡化相關因素和複雜的原因，需要多學科聯合治療。原發性勃起功能障礙通常由神經系統和血管因素引起，需要不同的治療強度和實證標準。次發性勃起功能障礙包括荷爾蒙和心理因素，器械治療策略通常需要與藥物和行為介入結合。年齡層（青年、中年、61歲以上）決定了產品的定位、對侵入性的接受度以及對產品壽命和維護的期望。

對材料和作用機制的考量是決定器械性能和法規核准的關鍵。材料類型包括彈性聚合物、金屬材料（如不銹鋼和鈦）、聚氨酯和矽膠，每種材料都有不同的生物相容性和機械性能。作用機制區分了液壓裝置和機械裝置，而動力來源（電池供電與手動）的差異會影響易用性、維護和臨床支援需求。最後，終端用戶環境和分銷管道（居家醫療、醫院、專科診所、線上平台、零售藥局以及包括專科醫療設備和外科用品商店在內的專業零售商）的特徵會影響產品的採用路徑、培訓需求和上市後支援義務。整合這些細分因素有助於發現有針對性的創新和客製化商業策略的機會，從而更好地反映臨床實際情況和患者偏好。

區域績效和策略要務（美洲、歐洲、中東和非洲、亞太地區）則著重於採用趨勢、報銷趨勢和供應方面的考量因素

區域趨勢差異顯著，因此美洲、歐洲、中東和非洲以及亞太地區需要採取不同的商業和監管策略。在美洲，完善的報銷系統和強大的醫院主導手術基礎有利於高複雜度植入方案的推廣，尤其是在療效持久且臨床醫生技術嫻熟的情況下，這些方案更容易被接受。同時，直接面對消費者的銷售管道以及對非侵入性治療方案日益成長的需求，正在擴大門診和居家治療的患者群體。這為那些既能減輕手術負擔又能維持臨床療效的價值提案創造了空間。

歐洲、中東和非洲地區（EMEA）的醫保報銷環境和監管流程各不相同，因此需要針對每個市場制定相應的證據支持和定價策略。在該地區，一些市場擁有先進的醫療保健體系，在提供充分的衛生經濟學證據後，能夠支持創新型治療器械；而另一些市場則對價格較為敏感，更傾向於選擇結構相對簡單、成本可預測的器械。與當地經銷商以及在採購體系和臨床實踐模式方面具有影響力的臨床意見領袖夥伴關係，對於建立信譽和促進市場准入至關重要。

亞太地區正經歷高所得市場快速普及和新興經濟體需求不斷成長的雙重局面。在許多市場，私人醫療服務的擴張和消費者健康素養的提高，為植入式和非侵入式醫療器材都創造了機會。然而，製造商必須應對不同的監管要求、當地的生產預期以及不同的臨床實踐模式。在整個亞太地區，臨床證據、報銷政策和分銷網路的策略性整合將決定醫療器材普及的速度和規模。

成熟製造商、專業創新者和分銷合作夥伴之間的競爭動態和企業策略驅動著產品系列、市場准入和臨床應用。

競爭格局呈現出成熟醫療設備製造商、專業創新企業和新興技術供應商並存的局面。主要企業透過臨床證據的累積、豐富的產品系列組合以及通路夥伴關係，在其核心市場保持著強勁的競爭力。關鍵的企業策略包括：迭代式產品開發以降低手術複雜性；材料創新以提高生物相容性和耐久性；以及透過有針對性的研究者主導試驗和真實世界結果註冊研究來培養臨床領導者。

對於那些尋求利用外部材料科學、電子學和治療能量技術等專業知識來補充自身能力的公司而言，戰略聯盟和許可協議十分常見。能夠整合售後服務模式（例如培訓項目、外科醫生支援和產品保固）的公司，能夠在初始銷售之後實現永續的差異化優勢。此外，將與醫院的直接關係與專業零售和線上通路結合的分銷策略，有助於擴大產品在各種終端用戶環境中的覆蓋範圍。

併購和少數股權投資仍然是獲取能力和加速市場准入的有效途徑，尤其是在涉及新型治療機制和數位健康相關技術時。那些保持臨床結果透明、投資與支付方合作並根據不斷變化的貿易政策調整製造地的公司，更有可能獲得競爭優勢。最終，公司的成功取決於其能否將創新產品線與切實可行的商業化計畫和穩健的供應鏈結構結合。

為製造商、臨床醫生和通路合作夥伴提供切實可行的優先建議，以加速臨床應用、增強市場進入並降低商業風險。

產業領導者應優先採取一系列切實可行的措施，將洞察轉化為可衡量的商業性成果。首先，投資於對比臨床證據和真實世界註冊研究，以證明器械在主要適應症、次要適應症和混合適應症中的耐用性、功能性結果和併發症情況。此類證據對於說服支付方和臨床醫生，以及在醫院採購過程中區分不同器材至關重要。其次，實現生產和供應商網路多元化，以降低關稅波動和單一來源依賴的風險，同時建立可追溯性和品管體系，用於監管申報。

第三，根據特定的人口統計和臨床細分市場，量身定做產品系列和商業化計劃，因為年齡層、功能障礙病因和最終用戶環境都會顯著影響器械的選擇。同時，最佳化材料和機制的選擇，以平衡性能、成本和監管風險。第四，制定混合通路策略，將與醫院的夥伴關係（用於複雜手術）與線上平台和專業零售商（用於微創解決方案和病患教育）結合。第五，儘早與支付方和衛生技術評估機構接洽，使證據生成與報銷標準保持一致，並探索反映長期價值而非僅僅初始成本的創新支付模式。

最後，我們正在建立一個適應性強的商業模式，整合了臨床醫生培訓、保固和服務以及數位化支援工具，旨在改善手術效果和患者滿意度。這些措施將強化產品定位，減少商業性摩擦，並加速永續推廣應用。

一套透明的調查方法，詳細闡述了資料來源、專家檢驗、分析框架、情境測試以及已知的局限性，從而為醫療設備市場提供可靠的洞察。

本分析的調查方法結合了第一手和第二手資料收集、結構化的分析框架以及與臨床和商業專家的反覆檢驗。第一手資料包括對臨床醫生、採購人員、分銷商和技術開發人員的訪談，旨在收集有關醫療設備性能、推廣障礙和分銷管道趨勢的經驗性見解。第二手資料來源包括同行評審的臨床文獻、監管指導文件、材料科學研究和已發表的政策分析，以對臨床和安全證據進行三角驗證。

此分析方法採用多維度細分映射，涵蓋產品、適應症、人口統計特徵、成分、作用機制、動力來源、最終用戶和分銷管道等多個方面，以識別高潛力交叉領域。情境分析用於壓力檢驗供應鏈和關稅對業務連續性和採購行為的影響。此調查方法強調假設的透明度，並在結論取決於可變輸入值時進行敏感度分析。研究結果會與獨立的臨床顧問和行業從業人員進行反覆檢驗，以確保其實際意義並完善解釋。

此調查方法存在一些局限性，例如區域醫保報銷環境的差異以及新治療方法臨床證據的不斷更新。在適當情況下，我們會指出資料缺口，並建議優先進行證據生成活動，以加強未來的評估。

整合市場促進因素、結構性風險和策略重點，為業務決策、投資選擇和產品藍圖圖制定提供資訊。

總之，勃起功能障礙醫療器材市場正處於轉折點，臨床創新、材料科學、監管環境以及不斷演變的通路共同構成了戰略要務。能夠整合可靠的實證醫學證據、強大的生產平台和客製化分銷策略的製造商，將更有利於把產品創新轉化為永續的商業性成功。關注患者偏好、人口趨勢和特定適應症的需求，將進一步提升產品與市場的契合度，並推動差異化價值提案。

監管政策的清晰度和支付方的合作仍然是提高產品普及率的關鍵基礎，尤其對於高度複雜的植入解決方案和新型治療方法更是如此。關稅環境和分銷經濟的變化凸顯了靈活的供應鏈結構和透明的成本管理策略的重要性。最終，能否在這個市場取得成功取決於能否將臨床驗證、業務永續營運和市場推廣可行性整合起來，從而為患者帶來可驗證的療效，並為醫療保健系統創造可預測的價值。

採用嚴謹的、以證據主導的產品開發和商業化方法的組織，將在不同的地理和醫療保健環境中創造機會，為在快速發展的治療領域取得長期領先地位奠定基礎。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 穿戴式神經調節設備在勃起功能障礙治療的應用日益廣泛
  • 消費保健Start-Ups正大力投資家用衝擊波治療設備。
  • 推出客製化3D列印陰莖支撐和真空療法配件
  • 將人工智慧診斷技術融入居家勃起功能障礙治療
  • 消費者對非侵入性電磁刺激解決方案的需求日益成長
  • 提高患者依從性的智慧PDE5抑制劑經皮吸收貼片的進展
  • 擴展數位健康平台，提供虛擬諮詢和設備追蹤功能
  • 透過泌尿系統診所和遠端醫療服務之間的合作，促進設備可近性
  • 在真空豎立裝置的製造過程中，重點使用環保和可回收材料。
  • 採用區塊鏈技術提升勃起功能障礙治療設備中的病患資料安全

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型分類的勃起功能障礙治療設備市場

  • 陰莖植入
    • 充氣式植入
    • 半剛性植入
  • 輔助器具
    • 夾緊裝置
    • 環形壓縮裝置
  • 治療設備
    • 低強度脈衝超音波設備
    • 衝擊波治療設備
  • 真空壓縮裝置

第9章 依適應症分類的勃起功能障礙治療器材市場

  • 混合型勃起功能障礙
    • 老齡化相關因素
    • 複雜原因
  • 原發性功能障礙
    • 神經系統因素
    • 血管因素
  • 次發性功能障礙
    • 荷爾蒙因素
    • 心理因素

第10章 按年齡層別分類的勃起功能障礙治療設備市場

  • 18至40歲
  • 41至60歲
  • 61歲或以上

第11章 按材料類型分類的勃起功能障礙治療器械市場

  • 由彈性體製成
  • 由金屬製成
    • 不銹鋼
    • 鈦
  • 聚氨酯
  • 矽酮

第12章：依作用機轉分類的勃起功能障礙治療器材市場

  • 油壓裝置
  • 機械執行器

第13章 按電源分類的勃起功能障礙治療設備市場

  • 電池供電
  • 手動輸入

第14章 依最終使用者分類的勃起功能障礙治療設備市場

  • 居家醫療
  • 醫院
  • 專科診所

第15章 勃起功能障礙治療器材市場（依通路分類）

  • 線上平台
  • 零售藥房
  • 專業零售商
    • 醫療設備專賣店
    • 外科用品商店

第16章 勃起功能障礙治療器材市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 勃起功能障礙治療器材市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 各國勃起功能障礙治療器材市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭情勢

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Advin Health Care
    • Alma Lasers Ltd.
    • Augusta Medical Systems LLC
    • Boston Scientific Corporation
    • Coloplast A/S
    • Comphya SA
    • DirexGroup
    • Dornier MedTech GmbH
    • Futura Medical Developments Limited
    • G.SURGIWEAR LTD.
    • Implantica Management AG
    • Medispec Ltd.
    • OHHMED Medical Ltd.
    • Owen Mumford Limited
    • PROMEDON GmbH
    • Rigicon, Inc.
    • STORZ MEDICAL AG
    • TE Inc.
    • TIMM Medical
    • Vacurect
    • Zimmer MedizinSysteme GmbH
    • ZSI Surgical Implants SRL
Product Code: MRR-1730A405FA49

The Erectile Dysfunction Devices Market is projected to grow by USD 2.80 billion at a CAGR of 6.35% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.71 billion
Estimated Year [2025] USD 1.81 billion
Forecast Year [2032] USD 2.80 billion
CAGR (%) 6.35%

Comprehensive overview of the current erectile dysfunction device landscape highlighting technological progress, stakeholder needs, and evolving patient care pathways

The introduction situates the current erectile dysfunction device landscape within a context of rapid clinical innovation, shifting reimbursement paradigms, and amplified patient expectations for minimally invasive solutions. Over recent years, technological advances have expanded the therapeutic toolkit beyond pharmacologic first-line therapies, creating room for implantable solutions, supportive devices that enhance sexual function, and noninvasive therapeutic modalities. These developments have coincided with a rising emphasis on patient-centered pathways, where convenience, discreet use, and quality-of-life outcomes drive adoption.

Stakeholders across clinical, manufacturing, and distribution channels are navigating a dynamic environment in which regulatory clarity and payor policies increasingly influence product design and go-to-market strategies. Clinicians are scrutinizing evidence of durability, complication rates, and functional outcomes, while procurement teams balance device performance with inventory and training costs. At the same time, patients are more engaged in treatment selection, valuing devices that align with lifestyle preferences and have transparent safety profiles. Against this backdrop, the market is differentiating along several dimensions including device mechanism, material composition, power source, and end-user context, all of which shape adoption patterns and competitive positioning.

This introductory synthesis establishes the imperative for manufacturers and investors to align clinical evidence, design innovation, and commercial execution. By connecting product attributes to real-world clinical pathways and distribution realities, organizations can better prioritize R&D resources and market entry tactics that resonate with both clinicians and patients.

How clinical innovation, regulatory recalibration, and shifting channel dynamics are converging to redefine value creation across the erectile dysfunction device ecosystem

Transformative shifts in this segment are driven by a convergence of clinical, technological, and market forces that are redefining value creation. Clinically, the movement toward minimally invasive and reversible solutions has elevated the importance of therapeutic devices such as low-intensity pulsed ultrasound and shockwave therapy, which offer non-surgical pathways and an expanded addressable patient base. Concurrently, innovations in implant design, including refinements in inflatable and semi-rigid implants, have prioritized reliability, ease of implantation, and patient comfort. These technical upgrades are increasingly influenced by material science advances across elastomeric polymers, silicones, metallic alloys such as stainless steel and titanium, and polyurethane formulations that balance biocompatibility with mechanical function.

From a regulatory and reimbursement perspective, clearer evidence thresholds and value-based procurement discussions are prompting manufacturers to generate comparative effectiveness and durability data earlier in development. This shift favors companies that can demonstrate meaningful outcomes across primary, secondary, and mixed indications, including aging-related, neurological, vascular, hormonal, and psychogenic etiologies. At the same time, distribution and channel evolution is reshaping access models: online platforms are lowering barriers to consumer engagement, while traditional specialist retailers and hospital procurement systems maintain their role for complex devices and procedures. Together, these dynamics are encouraging strategic partnerships between device makers, clinical stakeholders, and distribution partners to accelerate adoption while controlling cost and complexity.

In essence, the landscape is moving from product-centric propositions to integrated care solutions where evidence, usability, and channel strategy converge to determine commercial success.

Assessing the cumulative operational, commercial, and procurement impacts of United States tariffs implemented during 2025 on device supply chains and pricing strategies

The introduction of targeted tariff measures in 2025 has prompted stakeholders to reassess supply chain architecture, sourcing strategies, and cost pass-through dynamics. Manufacturers reliant on cross-border components, particularly for precision-engineered implants and electronic therapeutic devices, have faced elevated input costs and logistical complexity. In response, several manufacturing organizations are evaluating reshoring, nearshoring, or multi-sourcing approaches to mitigate tariff exposure while preserving quality control and regulatory compliance. Strategic suppliers with integrated manufacturing footprints and established quality systems have an advantage in absorbing or managing tariff volatility without compromising product continuity.

Beyond manufacturing, tariffs have influenced channel economics and pricing strategies. Retailers and specialty distributors have needed to balance margin pressures with competitive positioning, leading some to renegotiate supplier contracts or consolidate SKUs to maintain inventory turnover and price stability. Hospitals and specialty clinics are recalibrating procurement criteria to emphasize total cost of ownership and long-term service agreements, rather than unit price alone, to shield budgets from episodic tariff-driven spikes. Additionally, the policy environment has accelerated dialogues around bilateral supplier agreements and strategic inventory buffers to ensure continuity of care for elective procedures.

Critically, the tariff environment has reinforced the importance of transparent supplier traceability and component provenance for regulatory submissions. Companies that proactively document supply chain resilience, implement dual-sourcing strategies, and communicate cost management plans to payors and procurement stakeholders are better positioned to navigate uncertainty and preserve market access.

Segment-driven insights revealing product differentiation, indication complexity, demographic drivers, material selection, mechanism choices, and channel implications for strategic positioning

Segmentation insights reveal the multifaceted nature of product differentiation and the importance of aligning R&D and commercialization with clinical and end-user needs. When evaluating products by type, the landscape encompasses penile implants, supportive devices, therapeutic devices, and vacuum constriction devices. Penile implants themselves bifurcate into inflatable implants and semi-rigid implants, each presenting distinct trade-offs between mechanical complexity, patient satisfaction, and surgical training requirements. Supportive devices are categorized into clamping devices and ring constriction devices, which are generally positioned as adjunctive or less invasive options relative to implants. Therapeutic devices include low-intensity pulsed ultrasound devices and shockwave therapy devices that offer non-implantable, regenerative-focused modalities targeting underlying vascular or tissue conditions.

Indication-based segmentation adds further nuance. The market must be understood across mixed erectile dysfunction, primary erectile dysfunction, and secondary erectile dysfunction. Mixed erectile dysfunction frequently involves aging-related causes as well as combination etiologies that require blended treatment pathways. Primary erectile dysfunction is often driven by neurological and vascular causes that necessitate different therapeutic intensities and evidence thresholds. Secondary erectile dysfunction encompasses hormonal and psychogenic causes where device strategies often intersect with pharmacologic and behavioral interventions. Age group stratification-encompassing younger adult populations, middle-aged cohorts, and those 61 years and above-informs product positioning, tolerance for invasiveness, and expectations around longevity and maintenance.

Material and mechanism considerations are central to device performance and regulatory review. Material types span elastomeric polymers, metallic materials such as stainless steel and titanium, polyurethane, and silicone, each bringing distinct biocompatibility and mechanical properties to bear. Mechanisms of action contrast hydraulic action devices with mechanical action devices, and power-source differentiation between battery-powered and manual units affects usability, maintenance, and clinical support requirements. Finally, end-user context and distribution channel dynamics-home healthcare, hospitals, specialty clinics, online platforms, retail pharmacies, and specialist retailers including medical device stores and surgical supply stores-shape adoption pathways, training needs, and post-market support obligations. Synthesizing these segmentation layers highlights opportunities for targeted innovation and tailored commercial strategies that reflect clinical realities and patient preferences.

Regional performance and strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific highlighting adoption trends, reimbursement dynamics, and supply considerations

Regional dynamics vary substantially and mandate differentiated commercial and regulatory strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established reimbursement frameworks and a strong hospital-driven procedural base favor higher-complexity implantable solutions, particularly where durable outcomes and clinician familiarity reduce adoption friction. At the same time, direct-to-consumer channels and an increasing appetite for noninvasive therapeutic options are expanding the addressable patient base in ambulatory and home settings. This creates room for value propositions that reduce procedural burden while preserving clinical efficacy.

In Europe, Middle East & Africa, heterogeneous reimbursement landscapes and variable regulatory pathways require companies to localize evidence generation and pricing strategies. Some markets within this region have progressive reimbursement mechanisms that support innovative therapeutic devices when robust health-economic evidence is presented, while others remain price-sensitive and prefer lower-complexity devices with predictable cost profiles. Across procurement systems and clinical practice patterns, partnerships with regional distributors and clinical opinion leaders are instrumental in building credibility and facilitating market access.

Asia-Pacific presents a blend of rapid adoption among higher-income markets and rising demand in emerging economies. In many Asia-Pacific markets, the interplay between expanding private healthcare delivery and growing consumer healthcare literacy creates opportunities for both implantable and noninvasive devices. Nevertheless, manufacturers must navigate diverse regulatory requirements, local manufacturing expectations, and differing clinical practice patterns. Across all regions, strategic alignment between clinical evidence, reimbursement positioning, and distribution networks will determine the pace and scale of adoption.

Competitive dynamics and corporate strategies among established manufacturers, specialist innovators, and distribution partners that drive product portfolios, market entry, and clinical adoption

Competitive dynamics reflect a mixture of established medical device manufacturers, specialist innovators, and emerging technology providers. Leading companies leverage a combination of clinical evidence generation, product portfolio breadth, and channel partnerships to maintain traction in core markets. Key corporate strategies include iterative product development to reduce procedural complexity, material innovations that improve biocompatibility and longevity, and the cultivation of clinical champions through targeted investigator-initiated studies and real-world outcome registries.

Strategic collaborations and licensing agreements are common as firms seek to complement internal capabilities with external expertise in materials science, electronics, and therapeutic energy modalities. Companies that can integrate post-market service models-such as training programs, surgeon support, and product warranties-create sustainable differentiation that extends beyond the initial sale. Additionally, distribution strategies that blend direct hospital engagement with specialist retail and online channels improve access across diverse end-user contexts.

Mergers, acquisitions, and minority investments continue to be tools for capability acquisition and accelerated market entry, particularly when novel therapeutic mechanisms or digital health add-ons are involved. Firms that maintain transparency around clinical outcomes, invest in payer engagement, and adapt manufacturing footprints in response to trade policy shifts will likely secure competitive advantage. Ultimately, corporate success will be determined by the ability to align innovation pipelines with pragmatic commercialization plans and resilient supply chain architectures.

Practical and prioritized recommendations for manufacturers, clinicians, and channel partners to accelerate clinical adoption, strengthen market access, and mitigate commercial risk

Industry leaders should prioritize a set of pragmatic actions to convert insights into measurable commercial outcomes. First, invest in comparative clinical evidence and real-world registries that demonstrate device durability, functional outcomes, and complication profiles across primary, secondary, and mixed indications. Such evidence will be critical for convincing payors and clinicians, and for differentiating devices within hospital procurement processes. Second, diversify manufacturing and supplier networks to reduce exposure to tariff volatility and single-source dependencies, while documenting traceability and quality systems for regulatory submissions.

Third, tailor product portfolios and commercialization plans to specific demographic and clinical segments, recognizing that age group, etiology of dysfunction, and end-user setting materially influence device selection. Simultaneously, optimize material and mechanism choices to balance performance, cost, and regulatory risk. Fourth, develop hybrid channel strategies that combine hospital partnerships for complex procedures with online platforms and specialist retailers for less invasive solutions and patient education. Fifth, engage early with payors and health technology assessment bodies to align evidence generation with reimbursement criteria and to explore innovative payment models that reflect long-term value rather than upfront cost alone.

Finally, build adaptive commercial models that integrate clinician training, warranty and service offerings, and digital support tools to improve procedural outcomes and patient satisfaction. These steps will strengthen product positioning, reduce commercial friction, and accelerate sustainable adoption.

Transparent research methodology detailing data sources, expert validation, analytical frameworks, scenario testing, and acknowledged limitations to underpin robust device market insights

The research methodology underpinning this analysis combines primary and secondary data collection, a structured analytical framework, and iterative validation with clinical and commercial experts. Primary inputs include interviews with clinicians, procurement leaders, distributors, and technology developers to capture experiential insights on device performance, adoption barriers, and channel dynamics. Secondary sources comprise peer-reviewed clinical literature, regulatory guidance documents, materials science research, and publicly available policy analyses to triangulate clinical and safety evidence.

Analytical methods include segmentation mapping across product, indication, demographic, material, mechanism, power source, end-user, and distribution dimensions to identify high-opportunity intersections. Scenario analysis is used to stress-test supply chain and tariff impacts on operational continuity and procurement behavior. The methodology emphasizes transparency in assumptions, with sensitivity analyses performed where conclusions depend on variable inputs. Findings were iteratively validated with independent clinical advisors and industry practitioners to ensure practical relevance and to refine interpretive judgments.

Limitations of the methodology are acknowledged, including the variability of regional reimbursement environments and the evolving nature of clinical evidence for newer therapeutic modalities. Where appropriate, the report highlights data gaps and recommends priority evidence-generation activities to strengthen future assessments.

Concluding synthesis of market drivers, structural risks, and strategic priorities to inform executive decision-making, investment choices, and product roadmaps

In conclusion, the erectile dysfunction device landscape is at an inflection point where clinical innovation, material science, regulatory pragmatism, and channel evolution collectively shape strategic imperatives. Manufacturers that integrate robust evidence-generation with resilient manufacturing footprints and tailored channel strategies will be best placed to convert product innovation into sustainable commercial success. Attention to patient preferences, demographic trends, and indication-specific needs will further refine product-market fit and drive differentiated value propositions.

Regulatory clarity and payer engagement remain critical enablers for widespread adoption, particularly for higher-complexity implantable solutions and novel therapeutic modalities. The tariff environment and shifting distribution economics underscore the necessity for flexible supply chain architectures and transparent cost management strategies. Ultimately, success in this market will hinge on the ability to align clinical proof, operational resilience, and go-to-market execution in a way that delivers demonstrable outcomes for patients and predictable value for healthcare systems.

Organizations that adopt a disciplined, evidence-led approach to product development and commercialization will unlock opportunities across diverse geographies and care settings, positioning themselves for long-term leadership in a rapidly evolving therapeutic domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of wearable neuromodulation devices for erectile dysfunction management
  • 5.2. Surging investment in home-use shockwave therapy units by consumer medical startups
  • 5.3. Emergence of personalized 3D-printed penile support and vacuum therapy accessories
  • 5.4. Integration of artificial intelligence diagnostics into at-home erectile dysfunction treatment
  • 5.5. Growing consumer demand for noninvasive electromagnetic stimulation solutions
  • 5.6. Advancements in smart PDE5 inhibitor transdermal patches for sustained patient compliance
  • 5.7. Expansion of digital health platforms offering virtual counseling and device tracking features
  • 5.8. Collaborations between urology clinics and telemedicine services to promote device accessibility
  • 5.9. Focus on eco-friendly and reusable materials in vacuum erection device manufacturing processes
  • 5.10. Adoption of blockchain for secure patient data management in erectile dysfunction devices

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Devices Market, by Product Type

  • 8.1. Penile Implants
    • 8.1.1. Inflatable Implants
    • 8.1.2. Semi-Rigid Implants
  • 8.2. Supportive Devices
    • 8.2.1. Clamping Devices
    • 8.2.2. Ring Constriction Devices
  • 8.3. Therapeutic Devices
    • 8.3.1. Low-Intensity Pulsed Ultrasound Devices
    • 8.3.2. Shockwave Therapy Devices
  • 8.4. Vacuum Constriction Devices

9. Erectile Dysfunction Devices Market, by Indication

  • 9.1. Mixed Erectile Dysfunction
    • 9.1.1. Aging-Related Causes
    • 9.1.2. Combination Causes
  • 9.2. Primary Erectile Dysfunction
    • 9.2.1. Neurological Causes
    • 9.2.2. Vascular Causes
  • 9.3. Secondary Erectile Dysfunction
    • 9.3.1. Hormonal Causes
    • 9.3.2. Psychogenic Causes

10. Erectile Dysfunction Devices Market, by Age Group

  • 10.1. 18-40 Years
  • 10.2. 41-60 Years
  • 10.3. 61 Years And Above

11. Erectile Dysfunction Devices Market, by Material Type

  • 11.1. Elastomeric
  • 11.2. Metallic
    • 11.2.1. Stainless Steel
    • 11.2.2. Titanium
  • 11.3. Polyurethane
  • 11.4. Silicone

12. Erectile Dysfunction Devices Market, by Mechanism of Action

  • 12.1. Hydraulic Action Devices
  • 12.2. Mechanical Action Devices

13. Erectile Dysfunction Devices Market, by Power Source

  • 13.1. Battery-Powered
  • 13.2. Manual

14. Erectile Dysfunction Devices Market, by End-User

  • 14.1. Home Healthcare
  • 14.2. Hospitals
  • 14.3. Specialty Clinics

15. Erectile Dysfunction Devices Market, by Distribution Channel

  • 15.1. Online Platforms
  • 15.2. Retail Pharmacies
  • 15.3. Specialist Retailers
    • 15.3.1. Medical Device Stores
    • 15.3.2. Surgical Supply Stores

16. Erectile Dysfunction Devices Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Erectile Dysfunction Devices Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Erectile Dysfunction Devices Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Advin Health Care
    • 19.3.2. Alma Lasers Ltd.
    • 19.3.3. Augusta Medical Systems LLC
    • 19.3.4. Boston Scientific Corporation
    • 19.3.5. Coloplast A/S
    • 19.3.6. Comphya SA
    • 19.3.7. DirexGroup
    • 19.3.8. Dornier MedTech GmbH
    • 19.3.9. Futura Medical Developments Limited
    • 19.3.10. G.SURGIWEAR LTD.
    • 19.3.11. Implantica Management AG
    • 19.3.12. Medispec Ltd.
    • 19.3.13. OHHMED Medical Ltd.
    • 19.3.14. Owen Mumford Limited
    • 19.3.15. PROMEDON GmbH
    • 19.3.16. Rigicon, Inc.
    • 19.3.17. STORZ MEDICAL AG
    • 19.3.18. T.E. Inc.
    • 19.3.19. TIMM Medical
    • 19.3.20. Vacurect
    • 19.3.21. Zimmer MedizinSysteme GmbH
    • 19.3.22. ZSI Surgical Implants S.R.L.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. ERECTILE DYSFUNCTION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. ERECTILE DYSFUNCTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ERECTILE DYSFUNCTION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INFLATABLE IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SEMI-RIGID IMPLANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUPPORTIVE DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY CLAMPING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RING CONSTRICTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY THERAPEUTIC DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY LOW-INTENSITY PULSED ULTRASOUND DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SHOCKWAVE THERAPY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VACUUM CONSTRICTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MIXED ERECTILE DYSFUNCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGING-RELATED CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY COMBINATION CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRIMARY ERECTILE DYSFUNCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY NEUROLOGICAL CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY VASCULAR CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SECONDARY ERECTILE DYSFUNCTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HORMONAL CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PSYCHOGENIC CAUSES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 18-40 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 41-60 YEARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY 61 YEARS AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MATERIAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ELASTOMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY METALLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY TITANIUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POLYURETHANE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SILICONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANISM OF ACTION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HYDRAULIC ACTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MECHANICAL ACTION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY POWER SOURCE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY BATTERY-POWERED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MANUAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SPECIALIST RETAILERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY MEDICAL DEVICE STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SURGICAL SUPPLY STORES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY PENILE IMPLANTS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ERECTILE DYSFUNCTION DEVICES MARKET SIZE, BY SU